Understanding IgA Selective Deficiency and Its Impact on COVID-19
Epidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of Transmission: A Retrospective Cohort Study in Strasbourg University Hospital
University Hospital, Strasbourg, France · NCT06125457
This study looks at how having a specific immune deficiency affects people with COVID-19 and what symptoms they might experience.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France (other) |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06125457 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the epidemiology of selective IgA deficiency, focusing on its clinical manifestations and the associated risks, particularly in the context of COVID-19. It seeks to identify factors that contribute to the severity of symptoms in patients with this condition, who often require symptomatic treatment and monitoring for potential autoimmune issues. The study will analyze data from patients treated at the University Hospital in Strasbourg, France, over a specified period, to better understand the long-term implications of IgA deficiency.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of primary selective IgA deficiency.
Not a fit: Patients who do not have selective IgA deficiency or have expressed opposition to participating in the study may not benefit from this research.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management strategies for patients with IgA deficiency, particularly in relation to COVID-19.
How similar studies have performed: While there is limited research specifically on IgA deficiency and COVID-19, the study aims to fill a gap in understanding this condition's impact, suggesting a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Major subject (≥18 years old) * Subject treated at the HUS, with a primary selective IgA deficiency, considered as definitive (IgA concentration \< 0.07g/L or total absence of IgA on immunofixation) or as probable (IgA concentration lower than two standard leads to standard for age) with no other humoral immunodeficiency and no other cause of decreased gammaglobulins 01/01/2005 to 01/31/2022. * Subject having not expressed, after being informed, their opposition to the reuse of their data for the purposes of this research. Exclusion criteria: . Subject who expressed their opposition to participating in the study
Where this trial is running
Strasbourg
- Service d'Immunologie Clinique - Médecine Interne - CHU de Strasbourg - France — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: Anne-Sophie KORGANOW, MD, PhD
- Email: Anne-sophie.Korganow@chru-strasbourg.fr
- Phone: 33 3 69 55 05 21
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COVID-19, IgA deficiency, Antibiotic therapy, Immunosuppressive treatments, Autoimmune manifestations, Neoplasia